Sustainability
A global pioneer in the development of new drugs
Access to Healthcare
To ensure a healthy future for everyone, SK Biopharmaceuticals develops
and complies with a fair and transparent pricing policy
to deliver new values to our patients and healthcare professionals with reasonably priced pharmaceuticals.
Management
SK Biopharmaceuticals transforms patients' lives through innovative drug development and engages in continuous research targeting high-priority diseases
and healthcare system enhancement initiatives. SK Biopharmaceuticals implements its innovation by expanding the research areas with various therapeutic
modalities. Our ongoing efforts aim to improve healthcare accessibility by strengthening the healthcare infrastructure.
Our pricing governance guarantees that our decisions align with SK Biopharmaceuticals' pricing strategy, encompassing well-defined procedures and guidelines
that steer our approach to discounts.
The ESG/Strategic Committee within the Board of Directors oversees the management’s responsibilities and encourages the management's decision-making
toward the enhancement of global healthcare accessibility. It is essential to collaborate with relevant internal departments across SK Biopharmaceuticals in
order to manage risks and create healthcare value in the medium to long-term.
Targets
Create social value through the development of new drugs
-
Sustain the Patient Assistance Program
to enhance product accessibility -
Bolster the product pipeline and drive
performance improvement
to reach more patients in needs
By 2025, expand the product launch countries by more than twice compared to 2020
-
Explore entry into the MENA
and LATAM markets. -
Plans to have market entry
into South East Asia (SEA)
and the Commonwealth
of Independent States (CIS) -
Assess opportunities
to enter emerging markets
to improve healthcare accessibility
Performances
Enhancing Public Health in Various Countries
SK Biopharmaceuticals has actively built partnerships with local pharmaceutical companies to make new medicines as many as countries and is committed to strengthening healthcare systems and enhancing public health across the Middle East and North Africa as well as Latin America through the dissemination of training materials pertaining medicines. By imparting comprehensive medical acumen to the partners’ sales and medical representatives, SK Biopharmaceuticals uses its efforts to furnish accurate and precise insights on the judicious utilization of the medicine.Furthermore, SK Biopharmaceuticals is dedicated to supporting our partners by sharing the global commercial strategy and expertise, thereby ensuring the provision of the access to therapeutic alternatives to healthcare professionals and patients in a safe way. In addition, we ourselves pursue and promote for the partners to pursue early access or expanded access programs to enhance the accessibility of the medicines to the patients.
Our Efforts to Improve Pharmaceutical Supply Chain in Developing Countries
SK Biopharmaceuticals trusts our partners to conduct activities ranging from manufacturing, regulatory compliance, or distribution of medicines through their local supply chain providers. We endeavor to supply the active ingredient or drug products depending on the partner’s capability to ensure that the medicines are readily available and the partners could supply the medicines without shortage over the world including the developing countries. Furthermore, SK Biopharmaceuticals pursues that raw materials and components used in the supply chain are sourced responsibly with attention to minimizing environmental impact and takes responsibility for quality control and quality assurance of the medicines distributed in these regions. In addition, upon request by the partners, SK Biopharmaceuticals provides various protocols and shares expertise related to production of medicine and safety assessments through technology transfer and operates the joint steering committee with our partners in order to exchange valuable information about the commercialization of the medicines.Our Efforts to Improve Local R&D Capacity
While partners have autonomy to communicate with regulatory authorities and healthcare providers, based on the spirit of partnerships, SK Biopharmaceuticals supports local partners in conducting the development and regulatory activities to obtain market authorization from local government authorities. In particular, SK Biopharmaceuticals provides the partners with its regulatory documentation assistance and exchanges the regulatory information to facilitate the marketing authorization of medicines and accelerate the patients’ access to medicines in the MENA and LATAM areas.Our Supports for Post-marketing Surveillance in Developing Countries
SK Biopharmaceuticals collaborates closely with all partners in developing countries to continually detect and assess adverse events of the medicines. SK Biopharmaceuticals maintains a global safety database to accumulate safety data of the medicine being marketed globally, in order to analyze its risk/benefit profile which is used to support our partners to meet their regulations. Our partners are hence capable of coordinating all of required activities to perform pharmacovigilance and post-marketing surveillance.Our Intellectual Property Policy in Developing Countries
Although the protecting the medicines under the intellectual property rights is an important source of innovation in healthcare to motivate new drug development, SK Biopharmaceuticals recognizes the need for a flexible and multifaceted approach to intellectual property rights in order to contribute to solving the healthcare problems facing the least developed and low-income countries.While we plan to expand the territorial coverage of our medicines, we will not file patent applications or enforce our patent rights in the least developed countries defined by the UN and low-income countries the World Bank classifies.